Gianni L, et al. - The authors aim to determine if nab-paclitaxel improves the outcomes of early and locally advanced human epidermal growth factor receptor 2 (ERBB2/HER2)-negative breast cancer compared with paclitaxel when delivered in a neoadjuvant setting. Nab-paclitaxel resulted in no statistically significant improvement in the rate of pathological complete remission. As per the multivariate analysis, tumor subtype (triple-negative vs luminal B-like) was the most significant factor influencing treatment outcome.